Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Current Assets (2017 - 2025)

Historic Current Assets for Inmune Bio (INMB) over the last 9 years, with Q3 2025 value amounting to $30.7 million.

  • Inmune Bio's Current Assets fell 1445.15% to $30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.7 million, marking a year-over-year decrease of 1445.15%. This contributed to the annual value of $22.7 million for FY2024, which is 4326.27% down from last year.
  • Latest data reveals that Inmune Bio reported Current Assets of $30.7 million as of Q3 2025, which was down 1445.15% from $36.0 million recorded in Q2 2025.
  • Over the past 5 years, Inmune Bio's Current Assets peaked at $90.9 million during Q3 2021, and registered a low of $21.0 million during Q1 2025.
  • In the last 5 years, Inmune Bio's Current Assets had a median value of $45.6 million in 2023 and averaged $50.1 million.
  • In the last 5 years, Inmune Bio's Current Assets soared by 59271.46% in 2021 and then tumbled by 4756.77% in 2024.
  • Inmune Bio's Current Assets (Quarter) stood at $82.6 million in 2021, then decreased by 21.71% to $64.7 million in 2022, then crashed by 38.24% to $39.9 million in 2023, then tumbled by 43.26% to $22.7 million in 2024, then surged by 35.34% to $30.7 million in 2025.
  • Its Current Assets was $30.7 million in Q3 2025, compared to $36.0 million in Q2 2025 and $21.0 million in Q1 2025.